Serum levels of alpha-1 acid glycoprotein and pentraxin 3 in patients with Behcet's disease and relationship with disease activity

Basit Öğe Kaydı
dc.contributor.authorYazmalar, Levent
dc.contributor.authorBatmaz, Ibrahim
dc.contributor.authorSula, Bilal
dc.contributor.authorAlpayci, Mahmut
dc.contributor.authorAydin, Fatma
dc.contributor.authorTurkcu, Fatih
dc.contributor.authorYildiz, Mehmet
dc.date.accessioned2024-04-24T17:11:28Z
dc.date.available2024-04-24T17:11:28Z
dc.date.issued2015
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground To evaluate the relationship between disease activity and levels of alpha 1-acid glycoprotein and pentraxin 3 in patients with Behcet's disease (BD). Methods Forty-eight patients with BD and 29 age-and gender-matched healthy control subjects were included in the study. Serum pentraxin 3 levels were measured using enzyme-linked immunosorbent assay (ng/ml), and alpha 1-acid glycoprotein levels were measured using nephelometry (mg/dl). Disease activity was assessed using the BD Current Activity Form (BDCAF). Results Serum alpha-1 acid glycoprotein levels were significantly higher in patients with BD compared to the control group (P = 0.048). There were no significant differences between two groups in terms of levels of pentraxin 3 (P = 0.697). According to Pearson's analysis, alpha 1-acid levels are significantly positively correlated with erythrocyte sedimentation rate, C-reactive protein, and skin lesions and arthritis of BDCAF scores. Pentraxin 3 levels did not correlate with erythrocyte sedimentation rate, C-reactive protein, or any domains of BDCAF scores. Conclusion The results of the present study demonstrate that serum levels of alpha-1 acid glycoprotein were significantly higher in patients with BD relative to the control group. Alpha-1 acid glycoprotein is greatly associated with skin lesions and arthritis in patients with BD. We did not find high serum levels of PTX3 in patients with BD compared to healthy controls, and pentraxin 3 is not associated with disease activity in BD.en_US
dc.identifier.doi10.1111/ijd.12959
dc.identifier.endpageE400en_US
dc.identifier.issn0011-9059
dc.identifier.issn1365-4632
dc.identifier.issue10en_US
dc.identifier.pmid26147939
dc.identifier.scopus2-s2.0-84942191884
dc.identifier.scopusqualityQ1
dc.identifier.startpageE394en_US
dc.identifier.urihttps://doi.org/10.1111/ijd.12959
dc.identifier.urihttps://hdl.handle.net/11468/17540
dc.identifier.volume54en_US
dc.identifier.wosWOS:000363401700004
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofInternational Journal of Dermatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keyword]en_US
dc.titleSerum levels of alpha-1 acid glycoprotein and pentraxin 3 in patients with Behcet's disease and relationship with disease activityen_US
dc.titleSerum levels of alpha-1 acid glycoprotein and pentraxin 3 in patients with Behcet's disease and relationship with disease activity
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu